Surveillance and Diagnosis of Recurrent Urothelial Carcinoma

Introduction to Surveillance Guidelines

• The American Urological Association (AUA), American Society of Clinical Oncology (ASCO), and Society of Urologic Oncology (SUO) guidelines state that current urinary markers have a limited role in routine monitoring for recurrence after radical cystectomy due to false positive rates 1

Standard Surveillance Approach

• Urine cytology is the established standard for monitoring recurrence after TURBT and cystectomy, though interpretation difficulties exist after urinary diversion and radiation therapy can cause atypical results 1, 2
• The National Comprehensive Cancer Network (NCCN) guidelines recommend that for high-grade urothelial carcinoma, cytology should be performed every 3 months for the first 1-2 years, then at increasing intervals 3, 4, 5

FDA-Approved Urinary Biomarkers

• The NCCN guidelines note that consideration may be given to FDA-approved urinary biomarker testing using fluorescence in situ hybridization (FISH) or nuclear matrix protein 22 (NMP22) for monitoring recurrence, with a Category 2B recommendation 6, 7
• These tests have better sensitivity than cytology but lower specificity, and should not replace cystoscopy but may be considered as adjuncts during surveillance of high-risk disease 3, 8

Clinical Algorithm for High-Grade Recurrent Disease

• Primary surveillance for patients with a history of high-grade urothelial carcinoma should include cystoscopy every 3-6 months for the first 2 years, concurrent urine cytology at each cystoscopy visit, and upper tract imaging every 1-2 years 3, 4, 5
• Optional urinary tumor markers (Category 2B) may be added but should not replace cystoscopy 3, 8

Key Pitfalls to Avoid

• The AUA, ASCO, and SUO guidelines recommend that urinary markers should not be relied upon solely to replace cystoscopy, as no current marker has sufficient negative predictive value to safely omit cystoscopic surveillance 1, 3
• Urinary markers are not indicated for low-grade Ta tumors, and radiation therapy alters cytology interpretation, expecting atypical results that may not indicate recurrence 1, 2, 9

Guideline Recommendations for ctDNA Use in Bladder Cancer Surveillance

Current Guideline Position

• The 2024 AUA/ASCO/SUO guidelines do not recommend circulating tumor DNA (ctDNA) testing for routine surveillance after bladder cancer treatment, but acknowledge emerging evidence that ctDNA may help detect recurrence after radical cystectomy and could allow risk‑stratified reduction of imaging in patients with persistently undetectable ctDNA. 10

Standard Surveillance Recommendations

Non‑Muscle‑Invasive Bladder Cancer (NMIBC)

• Upper‑tract imaging (CT urography or MRI urography) is advised every 1–2 years for patients under surveillance for NMIBC. This recommendation is supported by NCCN and related oncology societies. [11][12]13

Muscle‑Invasive Bladder Cancer (MIBC) Post‑Radical Cystectomy

• Cross‑sectional imaging of the chest, abdomen, and pelvis (CT) should be performed at regular intervals that are determined by individual risk stratification after radical cystectomy. This imaging schedule is endorsed by the American College of Radiology. 14

Contraindications and Limitations of ctDNA

• ctDNA testing must not replace cystoscopic surveillance in patients who retain an intact bladder; cystoscopy remains the gold standard for detecting intravesical disease. 10
• ctDNA testing is not appropriate for the initial diagnostic work‑up of bladder cancer; definitive diagnosis requires cystoscopy with tissue biopsy. This limitation is highlighted by oncology consensus statements. 13